VK5211, a Novel Selective Androgen Receptor Modulator (SARM), Significantly Improves Lean Body Mass in Hip Fracture Patients: Results of a 12 Week Phase 2 Trial

被引：0

作者：

Ristic, Branko ^{[1
]}

Harhaji, Vladimir ^{[2
]}

Sirbu, Paul Dan ^{[3
]}

Irizarry-Roman, Moises ^{[4
]}

Bucs, Gabor ^{[5
]}

Sztanyi, Istvan ^{[5
]}

Binkley, Neil ^{[6
]}

Orwig, Denise ^{[7
]}

Neutel, Joel ^{[8
]}

Homer, Ken ^{[8
]}

Mancini, Marianne ^{[9
]}

Masamune, Hiroko ^{[9
]}

Barker, Geoff ^{[9
]}

Lian, Brian ^{[9
]}

机构：

[1] Clin Ctr Kragujevac, Clin Orthoped & Traumatol, Kragujevac, Serbia

[2] Clin Ctr Vojvodina, Clin Orthoped Surg & Traumatol, Novi Sad, Serbia

[3] Cty Hosp Emergency Sfintul Spiridon Iasi, Clin Sect Orthoped & Traumatol, Iasi, Romania

[4] Infinite Clin Res, Riverside, CA USA

[5] PTE AK Traumatol & Clin Surg, Pecs, Hungary

[6] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA

[7] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, College Pk, MD 20742 USA

[8] Integrium Clin Res, Tustin, CA USA

[9] Viking Therapeut Inc, San Diego, CA USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2018年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1072

引用

页码：24 / 24

页数：1

共 4 条

[1] A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys
Morimoto, Megumi
Yamaoka, Masuo
Hara, Takahito
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (01):
[2] The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
Dalton, James T.
Barnette, Kester G.
Bohl, Casey E.
Hancock, Michael L.
Rodriguez, Domingo
Dodson, Shontelle T.
Morton, Ronald A.
Steiner, Mitchell S.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (03) : 153 - 161
[3] VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial
Lian, Brian
Loomba, Rohit
Neutel, Joel
Margaritescu, Carmen
Homer, Ken
Luk, Amy
Mancini, Marianne
Ji, Summer
Barker, Geoff
Severance, Randall
Mohseni, Rizwana
Bernard, David
Dao, Michael
JOURNAL OF HEPATOLOGY, 2020, 73 : S53 - S53
[4] TOPLINE RESULTS FROM A 12-WEEK PHASE 2a TRIAL (DUET) EVALUATING TERN-501, A HIGHLY SELECTIVE THYROID HORMONE RECEPTOR (THR) BETA AGONIST, EITHER AS MONOTHERAPY OR IN COMBINATION WITH TERN-101, A NONSTEROIDAL FARNESOID X RECEPTOR (FXR) AGONIST, DEMONSTRATED SIGNIFICANT REDUCTIONS IN MR-BASED LIVER FAT CONTENT AND FIBROINFLAMMATION IN PATIENTS WITH PRESUMED MASH
Noureddin, Mazen
Alkhouri, Naim
Lawitz, Eric
Kowdley, Kris V.
Loomba, Rohit
Sanchez, William
Gonzales-Rojas, Yancicy
Kosinski, Joseph
Lee, Lois
Jones, Christopher
Quirk, Erin
Harrison, Stephen A.
HEPATOLOGY, 2024, 79 (02) : E33 - E33

← 1 →